ICON Research gains a regulatory expert, plus new executives for Exco InTouch, Avillion and others.
ICON has appointed Mary Pendergast, a regulatory expert, to a non-executive role on its board of directors.
The new director is also president of Pendergast Consulting, a firm which provides communications advice to biopharmaceutical companies. Previously, she was Executive VP of Government Affairs at Irish drug firm Elan, and a deputy commissioner at the US FDA.
Ms. Pendergast is also a board member of AesRx, ARCH Foundation and Impax Laboratories.
Copyright - Unless otherwise stated all contents of this web site are © 2015 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Recipharm, Catalent, INC and PRA completed eye-catching IPOs in 2014. Which firms are likely follow suit in 2015?